<DOC>
	<DOCNO>NCT00525005</DOCNO>
	<brief_summary>The purpose study determine efficacy combination docetaxel , oxaliplatin , S-1 ( DOS ) treatment advance gastric cancer .</brief_summary>
	<brief_title>Docetaxel , Oxaliplatin S-1 ( DOS ) Advanced Gastric Cancer</brief_title>
	<detailed_description>Docetaxel anti-microtubule agent . Docetaxel active agent gastric cancer , response rate ( RR ) 20-24 % single agent RR 37-40 % combination therapy 5-FU and/or cisplatin . S-1 new oral dihydropyrimidine dehydrogenase ( DPD ) inhibitory fluoropyrimidine ( DIF ) . In two late phase II study S-1 advance gastric cancer , RR 45 % , low ( 2 % ) incidence grade 3 toxicity . Recent phase I/II trial combination docetaxel S-1 patient advance gastric cancer suggest repeat 3-4 week cycle S-1 60-80mg/m2 /day 14 day combine docetaxel 40-75mg/m2 feasible . Oxaliplatin , diaminocyclohexane-platinum , alkylating agent inhibit DNA replication . Comparing cisplatin carboplatin , oxaliplatin appear effective favorable toxicity profile . Phase II study combination docetaxel oxaliplatin patient advance gastric cancer suggest docetaxel 60 75mg/m2 combine oxaliplatin 130 80mg/m2 every 3 week feasible . Recent dose find study combination docetaxel , oxaliplatin S-1 ( DOS ) patient advanced gastric cancer suggest docetaxel 52.5mg/m2 day 1 oxaliplatin 105mg/m2 day 1 combine S-1 80mg/m2 day1 day 14 every 3 week feasible . Docetaxel , S-1 oxaliplatin distinct mechanisms action overlap key toxicity . Furthermore , fluoropyrimidine docetaxel oxaliplatin show synergism vivo study clinical trial . Based result , combination DOS reasonable candidate new chemotherapeutic regimen advance gastric cancer .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirm gastric adenocarcinoma , initially diagnose recur Unresectable , locally advanced metastatic At least one unidimensional measurable lesion RECIST criterion Age 18 70 year old ECOG performance status ≤2 Estimated life expectancy ≥3 month Adequate bone marrow function ( WBCs ≥4,000/µL absolute neutrophil count ≥1,500/µL , platelets ≥100,000/µL ) , Adequate kidney function ( creatinine &lt; 1.5 mg/dL ) Adequate liver function ( bilirubin ≤1.8 mg/dL , transaminase level &lt; 2 time upper normal limit Written inform consent Other tumor type adenocarcinoma Previous history chemotherapy ( exception : adjuvant chemotherapy ) Presence CNS metastasis , psychosis , seizure Obvious bowel obstruction Evidence serious gastrointestinal bleeding Peripheral neuropathy ( NCI CTC &gt; = Grade I ) Past concurrent history neoplasm gastric adenocarcinoma , except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri Pregnant lactate woman , woman childbearing potential employ adequate contraception Other serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Stomach Neoplasm</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>S-1</keyword>
</DOC>